# A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

> **NCT02711852** · PHASE2 · COMPLETED · sponsor: **SecuraBio** · enrollment: 19 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** Duvelisib

## Key facts

- **NCT ID:** NCT02711852
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2020-05-04
- **Final completion:** 2020-05-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02711852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02711852, "A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02711852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*